Jon Northrup

CEO & Co-Founder

Mr. Northrup brings broad experience to Stingray, having worked at Eli Lilly and Company as a senior executive Corporate Business Development and Strategy, where he did over 40 deals on the buy side for Lilly, as well as in Finance, Marketing, and Sales; in management consulting with Asian companies, and in founding the venturing group with Jubilant Life Sciences.

Mr. Northrup is a Certified Licensing Professional in the Licensing Executive Society, received his MBA from the Wharton School of the University of Pennsylvania in Finance, and received his BA in Economics from Northwestern University.

Sunil Sharma - MD, FACP, MBA

Physician-in-Chief

Dr. Sharma is Deputy Director, Clinical Sciences; Professor and Division Director, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen); Chief, Translational Oncology Research & Drug Discovery; HonorHealth Research Institute.

Previously he was the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 phase 1-2 oncology clinical trials as primary investigator over the past 15 years. Dr. Sharma was a VP at Novartis in charge of their early clinical oncology program, started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world. 

Mohan Kaadige - PhD

Head of Biology

Dr. Kaadige is a research scientist with a deep passion for understanding the mechanisms and signaling pathways involved in the development and progression of cancer. At TGen, Dr. Kaadige works closely with Dr. Sharma to develop targeted cancer therapy programs. The team uses a combination of computational drug design, synthetic chemistry and biology to discover small molecule inhibitors for cancer therapy. Dr. Kaadige applies his skills to investigate proof of mechanism for novel inhibitors.

Monil Shah - Pharm D, MBA

VP of Development

Monil is a 20 year experienced pre-clinical and clinical drug developer, having worked at a number of biotech and pharmaceutical companies in this capacity, including WindMIL Therapeutics, IRX Therapeutics /Brooklyn ImmunoTherapeutics, Bristol Myers Squibb, Ventrus Biosciences, Assembly Biosciences, Celgene Corporation, Fibrogen, Novacea, Novartis, and Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers University in New Jersey and his MBA from Florida Institute of Technology.

Srinivas Kasibhatla - PhD

Chemistry

Srinivas has over 25 years of drug discovery experience in biotech and pharmaceutical companies, including 6 years of scientific leadership at BMS and developing the HSP-90 inhibitor which Conforma sold to Biogen. Srinivas has had a major role in multiple therapeutic classes and dozens of discovery programs across a number of companies.

Scott Jordan

Chief Business Officer

Mr. Jordan is an accomplished life sciences professional with more than 25 years of investment banking and corporate experience in negotiating strategic corporate alliances, securing international licensing agreements, building national sales teams, and contributing to successful product development, approval and launch. Prior to joining Stingray, Scott was an investment banker with Healthios Capital Markets and employed in business development and commercialization roles with NeoPharm, Akorn Ophthalmics, and Abbot Laboratories.

Mr. Jordan earned a BA from Michigan State University, Masters of Business Administration from Kellstadt Graduate School of Management (DePaul).

Alexis Weston

Senior Manager, Business Development - Biology

bio coming soon

Uma Bhatt - CPA

Chief Accounting Officer

Uma is an experienced controller and SVP, Accounting. She has worked at Iterion Therapeutics, Salarius Pharmaceuticals, both biotechs, previous to Stingray Therapeutics. She has also had a strong career in energy, covering both national and international accounting challenges.